Please login to the form below

Not currently logged in
Email:
Password:

QLT sells Acne drug to Allergan

QLT has entered into an agreement with Allergan for the sale of its worldwide rights to Aczone, a treatment gel for acne vulgaris
QLT has entered into an agreement with Allergan for the sale of its worldwide rights to Aczone, a treatment gel for acne vulgaris.

Under the terms of the agreement, QLT will receive a one-time payment of approximately $150m. Payment will be made upon closing of the deal, which is expected to take place in the Q3 2008.

Although licensed for treatment in the US and Canada over three years ago, Aczone was never marketed. QLT carried out further clinical trials after the FDA ordered a label restriction requiring blood screening before treatment. Earlier this year, the FDA removed the requirement for this restriction.

Bob Butchofsky, president and CEO of QLT said: "The divestment of Aczone is a major milestone for QLT and this transaction demonstrates that our persistence in completing the work needed to remove the blood monitoring restriction from the Aczone label in the United States provided significant value for our shareholders."

This is the second asset purchase agreement to divest non-core assets that the company has entered into since announcing its strategic restructuring earlier this year.

11th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics